You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
晨星:增長股及週期性股份估值差距收窄 可留意擁優勢大型股及追落後板塊
阿思達克 04-20 16:11
晨星亞洲股票研究總監陳麗子出席線上發布會時指,現時股市未算便宜,但亦非過份昂貴,故認為應聚焦於價值層面。她指出美國受惠刺激措施及拜登的基建計劃,而亞洲市場政策收緊的機率則較高,她估計通脹將增,加上十年期國債孳息率仍會向上,相關因素已反映在其估算內,料增長股或會因預期過高而首當其衝受影響。

她續指,增長股與週期性股份之間的估值差距已有所收窄,與去年底比較醫療健康板塊估值有所回調,而原材料、金融服務業、地產及能源行業等估值與去年底比較則回升。她認為在選股時可選擇行業內擁優勢的大型股份,以及選擇追落後的板塊,同時亦可留意派息增長吸引的股份以及可受惠利率上行的金融股等。

雖然受反壟斷調查等因素影響,她仍看好騰訊(00700.HK)、阿里(09988.HK)等龍頭股,以騰訊為例認為即使被罰公司亦有足夠現金流應對,不影響其業務及領導地位,雖有機會流失市場份額,但亦已反映在預期上,故無長期影響。

另外針對香港將提升股票印花稅,陳麗子認為市場最終會適應相關影響,不認為會影響到香港市場的吸引力,相信加幅對投資者來說仍可負擔。

出席同一場合的股票分析員李傑則指,在亞洲醫療健康板塊中首選金斯瑞生物科技(01548.HK),認為其細胞治療業務及非細胞治療業務增長前景強勁,同時對內地生物科技行業看法正面。(el/a) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account